凱賽生物(688065.SH):擬變更部分募投項目 用於“年產50萬噸生物基戊二胺及90萬噸生物基聚酰胺項目”
格隆匯1月11日丨凱賽生物(688065.SH)公佈,公司擬將募投項目“40000噸/年生物法癸二酸建設項目”募集資金投入金額由171,102萬元調整為50,125萬元,變更募集資金120,977萬元投入新項目“年產50萬噸生物基戊二胺及90萬噸生物基聚酰胺項目”。
“40000噸/年生物法癸二酸建設項目”由公司控股子公司凱賽(太原)生物技術有限公司(“太原技術”)實施,除前述調整外,其餘內容不變,此次變更導致的資金缺口將由合作方山西轉型工業園區集團有限公司按持股比例承擔以及太原技術自籌資金投入。
新項目名稱:年產50萬噸生物基戊二胺及90萬噸生物基聚酰胺項目;新項目總投資1,383,767.33萬元;新項目由公司控股子公司凱賽(太原)生物材料有限公司(“太原材料”)實施。
變更募集資金投向的金額:120,977.00萬元。
新項目預計正常投產時間:2023年
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.